On July 2, 2026, Ouster, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Northland Securities, Inc. as underwriter (the "Underwriter"), pursuant to which the Company agreed to issue and sell an aggregate of 3,621,876 shares (the "Firm Shares") of its common stock, par value $0.0001 per share ("Common Stock") to the Underwriter (the "Offering"). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriter a 30-day option, solely for the purpose of covering over-allotments, if any, to purchase up to an additional 543,281 shares of Common Stock (the "Optional Shares," and together with the Firm Shares, the "Shares"). The price to the public in the Offering was $55.22 per share.

The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-297220).

On July 6, 2026, the Company completed the sale and issuance of an aggregate of 3,621,876 shares of Common Stock. The Company received net proceeds of approximately $191.9 million, after deducting the Underwriter’s discounts and commissions.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The Company and the Company’s directors and executive officers also agreed not to sell or transfer any Common Stock for 60 days after July 2, 2026, without first obtaining the written consent of the Underwriter, subject to certain exceptions as described in the prospectus supplement.